Heartwire
- Alert FDA Reports Class 1 Recall of Medtronic TAVR Component
- Alert FDA Warns of LVAD-Associated Serious Adverse Events
- Alert FDA Reports Serious Adverse Events With Lariat Used for LAA Closure
- Approve PCSK9 Inhibitor Evolocumab, FDA Panel Recommends
- Alert EMA Committee Recommends Approval of Evolocumab
- Alert Contrave Safety Study Stopped, Investigators Livid
- Alert FDA Recalls TigerPaw II LAA Closure Device
- Alert EMA: Heart Risk From Amiodarone Plus Hepatitis C Antivirals
- Alert HCV Antiviral Simeprevir Label Warns of Cardiac Risk
- Alert Increased CV Risk With High-Dose Ibuprofen: EMA
- Alert FDA: Bradycardia Risk With Amiodarone Plus Hep-C Antivirals
- Alert Cardiac Surgeon Shot and Killed at Brigham and Women's Hospital
- Alert TCT St Jude Issues Worldwide 'Pause' on Portico TAVR Implants
- Alert No CV Risk With Olmesartan in Diabetics, Says FDA Review
- Alert CoreValve Indication Expanded to Include High-Risk Patients
- Alert FDA Review Finds No Increased Risk of MI With Dabigatran (Pradaxa)
- Alert EMA: Don't Combine ARBs, ACE-Is, and Direct Renin Inhibitors
- Alert Over 64 000 Bottles of Ranbaxy's Generic Lipitor Recalled
- Alert Thoratec Advises Heartmate II Retraining After Deaths
- Alert FDA Reviewing Saxagliptin Trial Data for Possible HF Risk